Well, we’ll, well, this seems very good news to start 2023 for Proteomics.

PIQ: CPT PLA reimbursement code approved in US for PromarkerD

The new code will take effect from 1 April 2023 and will herald in great news for diabetics at risk of developing diabetic kidney disease. Let’s hope this can create a situation where people are pre-diagnosed in time to do something to prevent this horrible disease from progressing to it’s inevitable life threatening end.

PIQ secures license for oesophageal cancer markers.

PIQ oesophageal cancer license.pdf.

This one is particularly important to me as I have a brother who died of Oesophageal cancer and hence I need to get screened regularly for Barrett’s disease as it has a hereditary component.

I really appreciate how PIQ is being proactive in looking for markers for diseases, hopefully giving the sufferers time to prevent them. That is SO much better than the usual reactive responses of the medical community.

i.e. Having a predisposition to oesophageal cancer means you can change your diet and eating habits to reduce reflux and hence prolong your period of good health.

Here are the slides from the Euroz Hartleys Institutional Conference, 8-10 March 2022.

PIQ ASX Investor Presentation 220310.pdf

I found the following encouraging.

They are revenue ready now! Just need to sort out mass production of their PromarkerD product.

They have some impressive targets for 2022. Some of which could be market/thesis proving for them. All steam ahead in Europe, let’s hope the US is quick to follow suite. Early detection, and hopefully prevention of Diabetic Kidney Disease will help so many sufferers, not to mention the cost savings with less need for dialysis and Kidney transplants. There is so much that so many can gain from what ProMarkerD has to offer.

Having PromarkerD for diagnosis of DKD out their in the world could help pave the way for all the other trials in their pipeline.

Proteomics out with some VERY promising news today.

ProMarkerD has entered the commercial stage and they are progressing with getting a claim number for its use in the US. This on top of brilliant trial results. And they have so many other uses for their technology in the pipe-line. Sounds really good.

Sounds especially good to help prevent some expensive to treat and debilitating diseases. Could this lead to an inflection point?

ASX Appendix 4C announcement

I really like Proteomics’ pipeline—the following taken from their Appendix 4C statement:

Disc: held IRL